Briefing
Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma
Tumor-informed Signatera testing was feasible in predominantly HPV-negative HNSCC; post-treatment ctDNA positivity was associated with worse progression-free survival (HR 7.33).
- Design: Evidence level 3
- Assay: Not named in the abstract
Clin Cancer ResPubMed 38824449DOI 10.1158/1078-0432.CCR-24-0590